Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03179605 · ClinicalTrials.gov registry record · Phase 2
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
A Phase 2 study, sponsored by Primus Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03179605 is a Phase 2 study that was terminated before completion, run by Primus Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT03179605, a Phase 2 study, was terminated before completion, sponsored by Primus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
Interventions
- DRUG DFD06
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-05-02 |
| Est. Completion | 2020-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03179605
The ClinicalTrials.gov registry entry for NCT03179605 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Primus Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DFD06 is the first listed.
NCT03179605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03179605 about?
NCT03179605 is a clinical study titled "Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06". The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
What is the current status of trial NCT03179605?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2017-05-02. Estimated completion is 2020-06-03.
What interventions are being tested in trial NCT03179605?
The interventions under investigation include: DFD06 (DRUG).
Who is sponsoring clinical trial NCT03179605?
This trial is sponsored by Primus Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.